|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CRLS1 |
Gene summary for CRLS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CRLS1 | Gene ID | 54675 |
| Gene name | cardiolipin synthase 1 | |
| Gene Alias | C20orf155 | |
| Cytomap | 20p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001101 | UniProtAcc | Q9UJA2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54675 | CRLS1 | LZE2T | Human | Esophagus | ESCC | 1.17e-02 | 2.38e-01 | 0.082 |
| 54675 | CRLS1 | LZE20T | Human | Esophagus | ESCC | 1.90e-02 | 8.32e-02 | 0.0662 |
| 54675 | CRLS1 | LZE24T | Human | Esophagus | ESCC | 1.88e-15 | 3.19e-01 | 0.0596 |
| 54675 | CRLS1 | P1T-E | Human | Esophagus | ESCC | 2.94e-09 | 5.03e-01 | 0.0875 |
| 54675 | CRLS1 | P2T-E | Human | Esophagus | ESCC | 1.06e-29 | 5.32e-01 | 0.1177 |
| 54675 | CRLS1 | P4T-E | Human | Esophagus | ESCC | 8.49e-52 | 1.21e+00 | 0.1323 |
| 54675 | CRLS1 | P5T-E | Human | Esophagus | ESCC | 4.43e-28 | 5.26e-01 | 0.1327 |
| 54675 | CRLS1 | P8T-E | Human | Esophagus | ESCC | 2.15e-26 | 4.50e-01 | 0.0889 |
| 54675 | CRLS1 | P9T-E | Human | Esophagus | ESCC | 1.25e-16 | 4.22e-01 | 0.1131 |
| 54675 | CRLS1 | P10T-E | Human | Esophagus | ESCC | 6.26e-45 | 9.09e-01 | 0.116 |
| 54675 | CRLS1 | P11T-E | Human | Esophagus | ESCC | 3.06e-17 | 6.73e-01 | 0.1426 |
| 54675 | CRLS1 | P12T-E | Human | Esophagus | ESCC | 8.34e-25 | 5.54e-01 | 0.1122 |
| 54675 | CRLS1 | P15T-E | Human | Esophagus | ESCC | 5.78e-30 | 5.77e-01 | 0.1149 |
| 54675 | CRLS1 | P16T-E | Human | Esophagus | ESCC | 4.27e-27 | 5.79e-01 | 0.1153 |
| 54675 | CRLS1 | P17T-E | Human | Esophagus | ESCC | 6.05e-05 | 2.33e-01 | 0.1278 |
| 54675 | CRLS1 | P19T-E | Human | Esophagus | ESCC | 6.00e-04 | 4.20e-01 | 0.1662 |
| 54675 | CRLS1 | P20T-E | Human | Esophagus | ESCC | 3.38e-23 | 4.97e-01 | 0.1124 |
| 54675 | CRLS1 | P21T-E | Human | Esophagus | ESCC | 6.00e-36 | 6.04e-01 | 0.1617 |
| 54675 | CRLS1 | P22T-E | Human | Esophagus | ESCC | 2.49e-14 | 1.92e-01 | 0.1236 |
| 54675 | CRLS1 | P23T-E | Human | Esophagus | ESCC | 1.02e-34 | 8.96e-01 | 0.108 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:00432007 | Esophagus | ESCC | response to amino acid | 74/8552 | 116/18723 | 6.23e-05 | 4.76e-04 | 74 |
| GO:000110110 | Esophagus | ESCC | response to acid chemical | 84/8552 | 135/18723 | 7.70e-05 | 5.74e-04 | 84 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:00464863 | Liver | NAFLD | glycerolipid metabolic process | 66/1882 | 392/18723 | 1.94e-05 | 5.52e-04 | 66 |
| GO:00466837 | Liver | NAFLD | response to organophosphorus | 28/1882 | 131/18723 | 9.05e-05 | 1.82e-03 | 28 |
| GO:00450174 | Liver | NAFLD | glycerolipid biosynthetic process | 43/1882 | 252/18723 | 3.83e-04 | 5.73e-03 | 43 |
| GO:00464742 | Liver | NAFLD | glycerophospholipid biosynthetic process | 33/1882 | 211/18723 | 6.93e-03 | 4.88e-02 | 33 |
| GO:00011013 | Liver | Cirrhotic | response to acid chemical | 52/4634 | 135/18723 | 2.65e-04 | 2.36e-03 | 52 |
| GO:0097066 | Liver | Cirrhotic | response to thyroid hormone | 15/4634 | 26/18723 | 3.43e-04 | 2.93e-03 | 15 |
| GO:00432002 | Liver | Cirrhotic | response to amino acid | 45/4634 | 116/18723 | 5.54e-04 | 4.36e-03 | 45 |
| GO:004668311 | Liver | Cirrhotic | response to organophosphorus | 45/4634 | 131/18723 | 8.57e-03 | 3.97e-02 | 45 |
| GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CRLS1 | SNV | Missense_Mutation | c.509C>A | p.Pro170Gln | p.P170Q | Q9UJA2 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CRLS1 | SNV | Missense_Mutation | rs749890487 | c.720N>A | p.Phe240Leu | p.F240L | Q9UJA2 | protein_coding | tolerated(0.45) | benign(0.037) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| CRLS1 | SNV | Missense_Mutation | novel | c.545N>C | p.Val182Ala | p.V182A | Q9UJA2 | protein_coding | deleterious(0.03) | benign(0.174) | TCGA-LL-A5YN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| CRLS1 | deletion | In_Frame_Del | c.758_769delNNNNNNNNNNNN | p.Ser256_Ala259del | p.S256_A259del | Q9UJA2 | protein_coding | TCGA-AA-3660-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| CRLS1 | SNV | Missense_Mutation | novel | c.338N>C | p.Leu113Ser | p.L113S | Q9UJA2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CRLS1 | SNV | Missense_Mutation | novel | c.394G>A | p.Asp132Asn | p.D132N | Q9UJA2 | protein_coding | tolerated(0.31) | benign(0.058) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CRLS1 | SNV | Missense_Mutation | rs753805913 | c.877N>T | p.Arg293Trp | p.R293W | Q9UJA2 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CRLS1 | SNV | Missense_Mutation | novel | c.431G>A | p.Gly144Glu | p.G144E | Q9UJA2 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CRLS1 | SNV | Missense_Mutation | novel | c.340T>C | p.Ser114Pro | p.S114P | Q9UJA2 | protein_coding | tolerated(0.08) | probably_damaging(0.959) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| CRLS1 | deletion | Frame_Shift_Del | novel | c.626delN | p.Tyr211MetfsTer26 | p.Y211Mfs*26 | Q9UJA2 | protein_coding | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |